Showing results (591-600 of 712) with videos related to
Sort By:
Pageof 72
Annals of Surgical Oncology|September 30, 2023
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical TrialOlga Kantor, Tari A King, Alyssa Jones, et al.International Journal of Molecular Sciences|June 2, 2021
Molecular Mechanisms of Fetal Tendon Regeneration Versus Adult Fibrous RepairIris Ribitsch, Andrea Bileck, Alexander D Aldoshin, et al.Breast Cancer Research and Treatment|October 7, 2020
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancerOtto Metzger Filho, Anita Giobbie-Hurder, Nancy U Lin, et al.Frontiers in Immunology|March 19, 2026
Sex-associated transcriptional changes to synovial macrophages in the aging jointMatthew Dapas, Erica N DeJong, Yidan Wang, et al.General and Comparative Endocrinology|December 1, 1987
The primary structure of coho salmon growth hormone and its cDNAC S Nicoll, S S Steiny, D S King, et al.Current Opinion in Genetics & Development|December 1, 1996
Exploiting the complete yeast genome sequenceD E Bassett, M A Basrai, C Connelly, et al.Science Translational Medicine|July 3, 2024
Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo modelsYusuf M Demirlenk, Hassan Albadawi, Zefu Zhang, et al.Breast Cancer Research and Treatment|September 25, 2013
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practiceKathryn J Ruddy, Stephen D Desantis, Rebecca S Gelman, et al.Breast Cancer Research and Treatment|May 7, 2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancerN U Lin, D S Seah, R Gelman, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 11, 2022
Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosisLena Wucherpfennig, Simon M F Triphan, Sabine Wege, et al.Pageof 72